<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03386591</url>
  </required_header>
  <id_info>
    <org_study_id>Naloxone P1a-003</org_study_id>
    <nct_id>NCT03386591</nct_id>
  </id_info>
  <brief_title>Comparison of Naloxone Pharmacokinetics</brief_title>
  <official_title>Comparison of Naloxone Pharmacokinetics Using Marketed Naloxone Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intranasal (IN) naloxone administration is an effective alternative to intravenous (IV) or
      intramuscular (IM) naloxone by emergency medical services for opioid overdoses and has been
      used successfully for this purpose as reported in clinical observational studies and a
      randomized controlled trial. Most of the published clinical studies concerning IN
      administration used an improvised kit of 2 mg naloxone/2 mL saline and a mucosal atomizer
      device (MAD), which is not FDA-approved for this indication. Pharmacokinetic (PK) data using
      these kits is not available in the published literature. This study is designed to determine
      the PK of naloxone following one and two IN administrations using the improvised kits
      compared to 2 and 4 mg delivered IN using the FDA-approved Narcan nasal spray device and 2 mg
      administered IM using the Evzio autoinjector.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Actual">March 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This will be an inpatient open-label, randomized, 5-period, 5-treatment, 5-sequence, crossover study involving approximately 30 healthy subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of naloxone</measure>
    <time_frame>11 days</time_frame>
    <description>Maximum plasma concentration, time of maximum observed concentration and area under the concentration-time curve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessments</measure>
    <time_frame>16 days</time_frame>
    <description>Number of participants with AEs, vital signs, ECG, laboratory changes and nasal irritation following the administration of naloxone.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Opioid-use Disorder</condition>
  <arm_group>
    <arm_group_label>Mucosal Atomization (1 administration)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Intranasal administration of 2 mL naloxone using a mucosal atomization device and syringe (1 mL/nostril)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucosal Atomization (2 administrations)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two Intranasal administrations of 2 mL naloxone using mucosal atomization device and syringe (1 mL/nostril) 2 minutes apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narcan 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Intranasal administration of 2 mg naloxone using Narcan nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Narcan 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Intranasal administration of 4 mg naloxone using Narcan nasal spray</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intramuscular auto injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One Intramuscular administration of 2 mg naloxone using Evzio auto-injector</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>Comparing pharmacokinetics of naloxone</description>
    <arm_group_label>Mucosal Atomization (1 administration)</arm_group_label>
    <arm_group_label>Mucosal Atomization (2 administrations)</arm_group_label>
    <arm_group_label>Narcan 2mg</arm_group_label>
    <arm_group_label>Narcan 4mg</arm_group_label>
    <arm_group_label>Intramuscular auto injector</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mucosal atomization device and syringe</intervention_name>
    <description>Injection</description>
    <arm_group_label>Mucosal Atomization (1 administration)</arm_group_label>
    <arm_group_label>Mucosal Atomization (2 administrations)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Narcan</intervention_name>
    <description>Nasal Spray</description>
    <arm_group_label>Narcan 2mg</arm_group_label>
    <arm_group_label>Narcan 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intramuscular Auto Injector</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Intramuscular auto injector</arm_group_label>
    <other_name>Evzio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 18 to 55 years of age, inclusive

          -  Provide written informed consent

          -  BMI ranging from 18 to 32 kg/m2, inclusive

          -  Adequate venous access

          -  No clinically significant concurrent medical conditions determined by medical history,
             physical examination, clinical laboratory examination, vital signs, and 12-lead ECG

          -  Male subjects must agree to use an acceptable method of contraception with female
             partners as well as not to donate sperm from the screening visit until 90 days after
             the last study drug administration

          -  Female subjects of childbearing potential must agree to use an acceptable method of
             birth control from the start of screening until 30 days after the last study drug
             administration. Oral contraceptives are prohibited

          -  Agree not to ingest alcohol, drinks containing xanthine &gt;500 mg/day (e.g., Coca ColaÂ®,
             coffee, tea, etc.), or grapefruit/grapefruit juice or participate in strenuous
             exercise 72 hours prior to admission through the last blood draw of the study

        Exclusion Criteria:

          -  Contact site directly for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Kelsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vince and Associates Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vince and Associates Clinical Research</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2017</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

